Why the study?
Does lipoprotein apheresis reduce lipoprotein(a) levels and cardiovascular events in patients with elevated lipoprotein(a)?
Does lipoprotein apheresis reduce lipoprotein(a) levels and cardiovascular events in patients with elevated lipoprotein(a)?
This systematic review suggests that lipoprotein apheresis is an effective therapy for lowering elevated lipoprotein(a) levels and reducing associated cardiovascular events.
Supports lipoprotein apheresis for elevated Lp(a); confirms efficacy across synthesized studies for event reduction.
Lipoprotein(a), which consists of a low-density lipoprotein (LDL) particle linked to an apolipoprotein(a) moiety, is currently considered an independent risk factor for cardiovascular disease due to its atherogenic (LDL-like) and prothrombotic (plasminogen-like) properties. The aim of this review is to provide an overview of the current and newer therapies for lowering increased lipoprotein(a) levels, focusing on lipoprotein apheresis. After a systematic literature search, we identified ten studies which, overall, documented that lipoprotein apheresis is effective in reducing increased lipoprotein(a) levels and cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Franchini et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: